abiraterone acetate / Generic mfg. - LARVOL DELTA

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. (PubMed, Eur Urol) - "Abiraterone-based treatment intensification did not increase FRH compared to SOC alone. In M1 disease, abiraterone reduced rather than augmented fracture risk, most plausibly reflecting improved metastatic bone disease control."

Journal • P3 data • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Prostate Cancer • Solid Tumor

Solitary Testicular Metastasis as the Only Site of Recurrence in Prostate Adenocarcinoma. (PubMed, Cureus) - "Postoperatively, systemic treatment was intensified using combined androgen deprivation therapy with abiraterone acetate, resulting in a marked decline in PSA levels...Diagnosis relies on advanced molecular imaging and immunohistochemistry, particularly in cases with reduced PSA expression. This case highlights the relevance of a multimodal strategy in oligometastatic disease, combining metastasis-directed surgery and intensified systemic therapy."

Journal • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • Testicular Cancer • KLK3

Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting. (PubMed, Cancers (Basel)) - " We analyzed deduplicated U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) reports from 2014 Q1 through 2026 Q1 in which abiraterone, enzalutamide, apalutamide, or darolutamide was the primary suspect drug. Disappearance of darolutamide-associated hematologic signals after documented docetaxel exclusion highlights the value of regimen-level sensitivity analyses in pharmacovigilance of combination cancer therapies. Persistent peripheral neuropathy requires external evaluation because residual confounding from unreported or prior neurotoxic treatment cannot be excluded."

Adverse events • Journal • Fatigue • Genito-urinary Cancer • Hematological Disorders • Oncology • Pain • Prostate Cancer • Solid Tumor

Oleanolic acid-selenocyanate hybrids trigger replication-associated DNA damage responses and suppress tumour growth in vitro and in vivo. (PubMed, Bioorg Chem) - "Biological evaluation against a panel of six human solid tumour cell lines identified several potent derivatives with GI50 values below 2.5 μM, representing up to a 19-fold improvement over native OA and markedly higher activity than the reference drug abiraterone and the widely-used CDDP (cisplatin) in multidrug resistant tumour cell lines. In vivo evaluation using Caenorhabditis elegans revealed excellent selectivity toward tumour tissues, with minimal toxicity in normal germlines and significant suppression of tumour germline growth. Collectively, these findings identify OA-selenocyanate hybrids as a promising class of tumour-selective antiproliferative agents acting through induction of DNA damage responses and disruption of cell-cycle progression."

Journal • Preclinical • Oncology • Solid Tumor • TP53BP1

Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors. (PubMed, Int J Mol Sci) - "Among AR T878A patients treated with enzalutamide, time to treatment discontinuation (TTD) was longer relative to patients with AR L702H (8 mo (95% CI 4.6-44 mo) vs. 3.5 mo (95% CI 2.3-5.5 mo) log-rank p < 0.0001) or AR amplification (7.7 mo (95% CI 4.7-15.8 mo) vs. 4.8 mo (95% CI 4-5.1 mo) (log-rank p = 0.0034). Among the AR T878A patients treated with abiraterone, TTD was not significantly different relative to patients with AR L702H, but longer relative to patients with AR amplification (7.1 mo (95% CI 5-8.5 mo) vs. 4.2 mo (95% CI 3.5-5.4 mo) (log-rank p = 0.037). This study provides hypothesis generating evidence that outcomes for patients with AR LBD mutations may differ by mutation subtype. AR T878A may be relatively more sensitive to ARPI treatment than AR L702H or amplified AR."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

MAGNITUDE: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (clinicaltrials.gov) - P3 | N=765 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Feb 2027 ➔ Dec 2027

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA • HRD

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2027 ➔ Jul 2028 | Trial primary completion date: Apr 2027 ➔ Jul 2028

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Seizure Disorders in Adults: Primary Care for Patients With Epilepsy. (PubMed, FP Essent) - "For patients with prostate-specific antigen levels greater than 40 ng/dL, a Gleason score of 9 or higher, or locally advanced prostate cancer, treatment with radiation therapy and androgen deprivation therapy can additionally include concurrent abiraterone plus prednisone for 2 years. Focal ablation is also an option for some patients. Prognosis varies by disease features; men with low-risk prostate cancer are much more likely to die from other causes, whereas those with distant metastases have a 5-year relative survival rate of 38.3%."

Journal • Review • CNS Disorders • Epilepsy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology

Eugonadal Progression-Free Survival Following Intensification of Metastasis-Directed Stereotactic Body Radiotherapy with Radioligand Therapy or Androgen Annihilation Therapy: A Comparison of Two Phase II Trials (ASTRO 2026) - P2 | "Whether an alternative strategy of adding androgen annihilation therapy (AAT; apalutamide plus abiraterone plus leuprolide) to SBRT would improve euPFS remains unknown. Both SBRT+RLT and SBRT+AAT improved euPFS over SBRT alone, while SBRT+RLT and SBRT+AAT achieved comparable euPFS. Given the numerical trend in grade =3 AEs favoring SBRT+RLT, in addition to the known quality of life impacts of hormonal therapy, SBRT+RLT appears to be a clinically attractive hormone-therapy sparing intensification strategy in men with oligorecurrent prostate cancer."

P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-world safety and outcomes of first-line (1L) olaparib plus abiraterone (OLA+ABI) in metastatic castration-resistant prostate cancer (mCRPC), and a comparison with docetaxel (DOC) (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Apalutamide versus abiraterone acetate in metastatic hormone-sensitive prostate cancer: an international propensity score-matched real-world analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Age-dependent differences in clinical benefit between abiraterone and enzalutamide in mCRPC: a post hoc analysis of the ProBio trial (ESMO 2026) - No abstract available

Clinical • Retrospective data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Optimizing sequencing under constraint: efficacy of low-dose abiraterone in metastatic castration-resistant prostate cancer from a real-world study in Thailand (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Survival Outcomes and Toxicity with Reduced-Dose ARPI Therapy: Rationale for the ENHANCE Phase III Trial (ASTRO 2026) - "Purpose/Objective(s): Androgen receptor pathway inhibitors (ARPIs), including enzalutamide, apalutamide, darolutamide, and abiraterone, are standard systemic therapies for metastatic hormone-sensitive (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). In this real-world cohort, ARPI dose reduction was independently associated with superior OS. This data supports the ENHANCE trial. ENHANCE is a UK multi-centre, open-label, phase III randomised non-inferiority trial comparing reduced-dose ARPI (50% standard dose) versus standard-dose ARPI (100%) in patients with mHSPC or mCRPC."

P3 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1) (ESMO 2026) - No abstract available

Clinical • P3 data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Darolutamide vs Abiraterone Triplet Therapy and Survival in U.S. Veterans with Newly Diagnosed Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (ESMO 2026) - No abstract available

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Clinical Validation of a Tissue-Based Next-Generation Sequencing Kit for Identifying Patients with BRCA1/2-Mutated Prostate Cancer for Niraparib + Abiraterone Acetate and Prednisone Therapy (ESMO 2026) - No abstract available

Biomarker • Clinical • Next-generation sequencing • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2

Ethnicity-Based Comparative Analysis of Treatment Endpoints of 30,000 Metastatic Castration Resistance Prostate Cancer Patients on Abiraterone and Enzalutamide (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Niraparib Plus Abiraterone and Prednisone in Metastatic Castration-Resistant Prostate Cancer: Results from the ProBio Platform Trial (ESMO 2026) - No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC) (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281 (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

IDeate-Prostate02: A PHASE 1/2, OPEN-LABEL UMBRELLA SUBSTUDY OF IFINATAMAB DERUXTECAN-BASED TREATMENT COMBINATIONS OR AS MONOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (SUO 2025) - P1/2 | "Two monotherapy arms (Arm 1 [docetaxel] and Arm 2 [I-DXd]) will enroll participants into the Efficacy Phase, and 2 I-DXd combination arms (Arm 3: I-DXd+MK-5684; and Arm 4: I-DXd+ARPI [abiraterone acetate or enzalutamide; prior treatment dependent]) will enroll into the Safety Lead-in, followed by Efficacy Phase. Recruitment is ongoing. "

Clinical • Metastases • Monotherapy • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD276

Recurrent Melena Secondary to Diffuse Gastric Metastases From Prostate Adenocarcinoma: A Rare Case Report (ACG 2026) - "His androgen deprivation therapy was resumed, and he was set up for outpatient initiation of abiraterone acetate...Diagnosis relies heavily on biopsy of the abnormal tissue for histopathology and immunohistochemical evaluation. Figure: Endoscopic view of the gastric body"

Case report • Clinical • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Nephrology • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Disease • Solid Tumor • CDX2 • PTPRC

Apalutamide-Associated Cholestatic Liver Injury in Metastatic Prostate Cancer (ACG 2026) - "Unlike abiraterone (androgen biosynthesis inhibitor), it does not carry a specific FDA hepatotoxicity warning or routine liver function test monitoring requirement. Figure: Figure 1. Hepatic recovery over 72 hours demonstrates a 42% reduction in alkaline phosphatase (ALP), with concurrent downtrending transaminases and modest improvement in total bilirubin between admission (Day 0) and Day 3."

Metastases • Castration-Resistant Prostate Cancer • Chronic Obstructive Pulmonary Disease • Genito-urinary Cancer • Hepatology • Hormone Sensitive Prostate Cancer • Hypertension • Immunology • Liver Failure • Oncology • Prostate Cancer • Pulmonary Disease • Respiratory Diseases • Solid Tumor